ADCT NYSE
ADC Therapeutics S.A.
1W: +4.6%
1M: +26.2%
3M: +44.5%
YTD: -54.8%
1Y: -61.1%
3Y: +91.6%
5Y: -93.8%
$1.59
+0.08 (+5.30%)
Weekly Expected Move ±17.5%
$1
$1
$1
$2
$2
Credit Risk of going bust: higher than 95% of companies Debt: 67.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.46 (down 71%), ADC Therapeutics S.A. would be worth roughly what it owes.
Total debt $417.1M against a stock market value of $203.0M.
Distance to default 0.64 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $211.6M (short-term plus half of long-term), stock volatility 116.6%; Altman Z'' -18.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $417.1M against a stock market value of $203.0M.
Distance to default 0.64 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $211.6M (short-term plus half of long-term), stock volatility 116.6%; Altman Z'' -18.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships2
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2024-01-24
Earliest Filing
2026-02-23
Latest Filing
investor: 2
Counterparties (Filed by ADCT)
2 relationshipsCompanies named in ADCT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| HealthCare Royalty Management, LLC | — | investor | Provider of $300 million funding with amended change of control and buyout obligations. | 2026-02-23 | View |
| Redmile Group, LLC | — | investor | Agreement regarding preemptive rights and advance subscription rights with respect to shares of ADC Therapeutics SA. | 2024-01-24 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-13 | Material Agreement; Earnings Release; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-08-13 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-07-02 | Officer/Director Change | View | |
| 2026-06-24 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-03 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-02 | Shareholder Vote; Exhibits | View | |
| 2026-05-04 | Earnings Release; Exhibits | View | |
| 2026-03-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-23 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-08 | Results of Operations and Financial Condition; Regulation FD Disclosure | View | |
| 2025-12-05 | Other Events | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-14 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Unregistere | Agreement | View |
| 2025-09-30 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-12 | Entry into Material Definitive Agreement; Costs Associated with Exit or Disposal Activities; Unregis | Agreement | View |
| 2025-06-05 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR